The purpose of this research study is to see if combining uracil cream (UTC) with capecitabine (Xeloda) can prevent Hand-Foot Syndrome. The study will also see what effects UTC and capecitabine may have in patients with metastatic breast cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Grade 2 and 3 HFS as graded by Roche Criteria
Timeframe: Maximum of 6 months of therapy
Serum Pharmacokinetic Levels of Uracil will be drawn
Timeframe: Maximum of 6 months of therapy